109 related articles for article (PubMed ID: 1697448)
1. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass.
Doherty DC; Ortel TL; de Bruijn N; Greenberg CS; Van Trigt P
Anesthesiology; 1990 Sep; 73(3):562-5. PubMed ID: 1697448
[TBL] [Abstract][Full Text] [Related]
2. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis.
Rowlings PA; Mansberg R; Rozenberg MC; Evans S; Murray B
Aust N Z J Med; 1991 Feb; 21(1):52-4. PubMed ID: 1709804
[TBL] [Abstract][Full Text] [Related]
3. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs.
Henny CP; Ten Cate H; Ten Cate JW; Moulijn AC; Sie TH; Warren P; Büller HR
J Lab Clin Med; 1985 Aug; 106(2):187-96. PubMed ID: 4020247
[TBL] [Abstract][Full Text] [Related]
4. Clinical use of heparin fractions, fragments, and heparinoids.
Messmore HL
Semin Thromb Hemost; 1985 Apr; 11(2):208-12. PubMed ID: 2412297
[No Abstract] [Full Text] [Related]
5. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
Meuleman DG
Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
[TBL] [Abstract][Full Text] [Related]
6. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
Ortel TL; Gockerman JP; Califf RM; McCann RL; O'Connor CM; Metzler DM; Greenberg CS
Thromb Haemost; 1992 Mar; 67(3):292-6. PubMed ID: 1379384
[TBL] [Abstract][Full Text] [Related]
7. In vivo activity of a new heparinoid.
Ockelford PA; Carter CJ; Hirsh J
Pathology; 1985 Jan; 17(1):78-81. PubMed ID: 4000717
[TBL] [Abstract][Full Text] [Related]
8. Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: successful anticoagulation with the low-molecular-weight heparinoid Org 10172 during haemodialysis.
Greinacher A; Philippen KH; Kemkes-Matthes B; Möckl M; Mueller-Eckhardt C; Schaefer K
Nephrol Dial Transplant; 1993; 8(10):1176-7. PubMed ID: 7505906
[No Abstract] [Full Text] [Related]
9. Studies of Org 10172 in patients with acute ischemic stroke. TOAST Study Group.
Adams HP; Woolson RF; Biller J; Clarke W
Haemostasis; 1992; 22(2):99-103. PubMed ID: 1379970
[TBL] [Abstract][Full Text] [Related]
10. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.
Turpie AG; Levine MN; Hirsh J; Carter CJ; Jay RM; Powers PJ; Andrew M; Magnani HN; Hull RD; Gent M
Lancet; 1987 Mar; 1(8532):523-6. PubMed ID: 2434815
[TBL] [Abstract][Full Text] [Related]
11. Orgaran (Org 10172): its pharmacological profile in experimental models.
Meuleman DG
Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
[TBL] [Abstract][Full Text] [Related]
12. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment.
Ireland H; Lane DA; Flynn A; Anastassiades E; Curtis JR
Thromb Haemost; 1986 Apr; 55(2):271-5. PubMed ID: 3715791
[TBL] [Abstract][Full Text] [Related]
13. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease.
Ten Cate H; Henny CP; Büller HR; Ten Cate JW; Magnani HN
Ann Neurol; 1984 Mar; 15(3):268-70. PubMed ID: 6721448
[TBL] [Abstract][Full Text] [Related]
14. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
[TBL] [Abstract][Full Text] [Related]
15. Heparinoids Danaparoid and Sulodexide as clinically used drugs.
Dou H; Song A; Jia S; Zhang L
Prog Mol Biol Transl Sci; 2019; 163():55-74. PubMed ID: 31030761
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis.
Henny CP; ten Cate H; Surachno S; Stevens P; Büller HR; den Hartog M; ten Cate JW
Thromb Haemost; 1985 Aug; 54(2):460-2. PubMed ID: 2417351
[TBL] [Abstract][Full Text] [Related]
17. Treatment of heparin-induced thrombocytopenia with thrombosis by new heparinoid.
Harenberg J; Zimmermann R; Schwarz F; Kübler W
Lancet; 1983 Apr; 1(8331):986-7. PubMed ID: 6132291
[No Abstract] [Full Text] [Related]
18. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications.
Henny CP; Ten Cate H; Ten Cate JW; Surachno S; van Bronswijk H; Wilmink JM; Ockelford PA
Lancet; 1983 Apr; 1(8330):890-3. PubMed ID: 6132219
[TBL] [Abstract][Full Text] [Related]
19. Use of a low molecular weight preparation of heparin--ORG 10172 (Lomoparan) in the critically ill.
John G; Shehabi Y; Mudaliar Y
Anaesth Intensive Care; 1991 Nov; 19(4):588-91. PubMed ID: 1721505
[No Abstract] [Full Text] [Related]
20. Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172).
Greinacher A; Eckhardt T; Mussmann J; Mueller-Eckhardt C
Thromb Res; 1993 Jul; 71(2):123-6. PubMed ID: 7689764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
